Weiss Multi-Strategy Advisers’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-20,319
Closed -$1.98M 838
2020
Q3
$1.98M Buy
20,319
+226
+1% +$26K 0.05% 349
2020
Q2
$2.47M Buy
20,093
+1,882
+10% +$214K 0.07% 303
2020
Q1
$1.59M Buy
18,211
+211
+1% +$22.3K 0.06% 266
2019
Q4
$1.88M Buy
18,000
+6,000
+50% +$673K 0.03% 427
2019
Q3
$1.38M Hold
12,000
0.03% 417
2019
Q2
$2.07M Sell
12,000
-8,000
-40% -$1.38M 0.05% 302
2019
Q1
$3.37M Sell
20,000
-4,000
-17% -$595K 0.08% 256
2018
Q4
$2.34M Buy
24,000
+11,500
+92% +$1.51M 0.1% 216
2018
Q3
$2.16M Sell
12,500
-5,233
-30% -$755K 0.06% 323
2018
Q2
$2.47M Sell
17,733
-2,267
-11% -$322K 0.06% 316
2018
Q1
$2.25M Buy
+20,000
New +$2.51M 0.07% 304

Other funds holding GWPH

Weiss Multi-Strategy Advisers's GWPH Position: Q4 2020 in Review

Weiss Multi-Strategy Advisers sold out of GW Pharmaceuticals Plc American Depositary Shares (GWPH) in Q4 2020, closing a stake of 20,319 shares — an estimated $1.98M sold.

Weiss Multi-Strategy Advisers first reported a position in GWPH in Q1 2018 and held it in 11 quarters. The position peaked at $3.37M in Q1 2019. 279 funds tracked by Wall St. Rank hold GWPH as of Q4 2020.

  • Weiss Multi-Strategy Advisers reported no remaining GW Pharmaceuticals Plc American Depositary Shares position as of Q4 2020 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 20,319 GW Pharmaceuticals Plc American Depositary Shares shares in Q4 2020, an estimated $1.98M.
  • Weiss Multi-Strategy Advisers first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q1 2018 and held it in 11 quarters.
  • Weiss Multi-Strategy Advisers's GW Pharmaceuticals Plc American Depositary Shares position peaked at $3.37M in Q1 2019.
  • 279 funds tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q4 2020.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.